{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mFOLFOX&page=2", "query": { "intervention": "mFOLFOX", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mFOLFOX&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-11T07:47:29.093Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05458219", "title": "A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Unresectable or Metastatic Solid Tumors" ], "interventions": [ { "name": "IBI343", "type": "DRUG" }, { "name": "FOLFIRINOX/mFOLFIRINOX", "type": "DRUG" }, { "name": "mFOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 470, "start_date": "2022-10-26", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-09-11T07:47:29.093Z", "location_count": 3, "location_summary": "Austin, Texas • Irving, Texas • San Antonio, Texas", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Irving", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05458219" }, { "nct_id": "NCT03488667", "title": "Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastro Esophageal Junction Cancer", "Stomach Cancer", "Adenocarcinoma" ], "interventions": [ { "name": "Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab", "type": "DRUG" }, { "name": "Adjuvant Treatment - mFOLFOX & Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 40, "start_date": "2018-06-27", "completion_date": "2025-04-30", "has_results": false, "last_update_posted_date": "2023-05-19", "last_synced_at": "2026-09-11T07:47:29.093Z", "location_count": 1, "location_summary": "Westwood, Kansas", "locations": [ { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03488667" }, { "nct_id": "NCT04643366", "title": "Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2021-01-28", "completion_date": "2032-01-31", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-09-11T07:47:29.093Z", "location_count": 4, "location_summary": "Richmond, Virginia • South Hill, Virginia • Tappahannock, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" }, { "city": "South Hill", "state": "Virginia" }, { "city": "Tappahannock", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04643366" }, { "nct_id": "NCT01658943", "title": "Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Acinar Cell Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Recurrent Pancreatic Carcinoma", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2012-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-03-09", "last_synced_at": "2026-09-11T07:47:29.093Z", "location_count": 534, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 350 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01658943" }, { "nct_id": "NCT02671435", "title": "A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Monalizumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 383, "start_date": "2016-02-22", "completion_date": "2027-07-30", "has_results": true, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-09-11T07:47:29.093Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02671435" }, { "nct_id": "NCT03611556", "title": "MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma", "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Oleclumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Folinic acid", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 213, "start_date": "2018-06-21", "completion_date": "2022-07-22", "has_results": true, "last_update_posted_date": "2023-10-03", "last_synced_at": "2026-09-11T07:47:29.093Z", "location_count": 18, "location_summary": "La Jolla, California • Aurora, Colorado • Fort Myers, Florida + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03611556" }, { "nct_id": "NCT03781323", "title": "Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Rectal Cancer" ], "interventions": [ { "name": "FOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2019-05-03", "completion_date": "2027-06-01", "has_results": true, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-11T07:47:29.093Z", "location_count": 2, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03781323" }, { "nct_id": "NCT04526886", "title": "Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colorectal Cancer", "Gastric Cancer", "Esophageal Cancer", "Ampullary Cancer", "Small Bowel Cancer", "Appendix Cancer" ], "interventions": [ { "name": "Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2020-10-15", "completion_date": "2023-03-07", "has_results": true, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-09-11T07:47:29.093Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT04526886" }, { "nct_id": "NCT07432295", "title": "Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Advanced Cancer", "Metastatic Cancer", "Gastric Cancer", "Gastroesophageal Junction Carcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "Givastomig", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "5Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "I-Mab Biopharma US Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2026-02-11", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-09-11T07:47:29.093Z", "location_count": 3, "location_summary": "Goodyear, Arizona • Duarte, California • Boston, Massachusetts", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07432295" }, { "nct_id": "NCT04164069", "title": "Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Colorectal Carcinoma", "Metastatic Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Stage II Colon Cancer", "Stage II Rectal Cancer", "Stage III Colon Cancer", "Stage III Rectal Cancer", "Esophageal Cancer", "Pancreatic Cancer", "Bile Duct Cancer", "Gastric Cancer", "Gall Bladder Cancer", "Small Bowel Adenocarcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Anne Noonan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2020-09-02", "completion_date": "2023-06-22", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-09-11T07:47:29.093Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04164069" } ] }